Previous 10 | Next 10 |
home / stock / bnoef / bnoef news
The excitement from FDA approval of Biogen’s Alzheimer’s drug Aduhelm is subsiding. The FDA is being scrutinized about the approval, and key hospitals are not prescribing Aduhelm. The fall in Biogen share price reflects Aduhelm seen as not an effective treatment for ...
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial PR Newswire Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder ...
Bionomics Announces Plans to Conduct U.S. Initial Public Offering PR Newswire ADELAIDE, Australia , Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announ...
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD PR Newswire ADELAIDE, Australia , July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) ( Bionomics or Company ), a global, clinical stage biopharmaceutical company, is pleased t...
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...
Solid formulation of BNC210 better and faster administration than liquid formulation. Bionomics PTSD Phase 2b trial will start soon with a tablet formulation. BNC210 has previously shown benefit for Social Anxiety Disorder, but the speed of effect was not consistent with acute tre...
Bionomics BNC210 Expansion into Social Anxiety Disorder PR Newswire Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder BNC210 Phase 2b PTSD trial on target for start in...
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomic...
Investment supports phase IIb clinical trial examining novel PTSD treatment TORONTO, ON / ACCESSWIRE / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to a...
News, Short Squeeze, Breakout and More Instantly...
Bionomic Ltd Par Ord Company Name:
BNOEF Stock Symbol:
OTCMKTS Market:
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...